Testing

Dr. Leslie Donato recently joined “Laborastories: The Podcast,” hosted by the Association for Diagnostics & Laboratory Medicine (ADLM) president Dr. Anthony Killeen, to discuss the publication of the new ADLM lipid and lipoprotein testing document. The document highlights best practices and new guidance regarding lipid and lipoprotein testing to ensure the best care for patients with heart disease, while educating clinical laboratorians on the most recent evidence-based improvements in the testing space.

By Jack Gilligan • October 23, 2024

Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many kinds of cancer.

By Barbara J. Toman • October 22, 2024

This page lists updates posted to Mayo Clinic Labs during the month of September.

By Michael Hutchison • October 2, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

By Barbara J. Toman • September 24, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

By Barbara J. Toman • September 17, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

By Barbara J. Toman • September 10, 2024

This page lists updates posted to Mayo Clinic Labs during the month of August.

By Michael Hutchison • September 5, 2024

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

By Barbara J. Toman • August 6, 2024

This page includes updates posted to Mayo Clinic Labs during the month of July.

By Michael Hutchison • August 2, 2024

This page includes updates posted to Mayo Clinic Labs during the month of June.

By Michael Hutchison • July 2, 2024

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

By Barbara J. Toman • June 11, 2024

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.

By Barbara J. Toman • June 4, 2024

This page includes updates posted to Mayo Clinic Labs during the month of May.

By Michael Hutchison • June 3, 2024